Michael Hoffman Latest Insider Activity
Management EfficiencyThe company has return on total asset (ROA) of (65.92) % which means that it has lost $65.92 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (276.06) % meaning that it created substantial loss on money invested by shareholders.
Entity SummaryOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 25 people.Onconova Therapeutics (ONTX) is traded on BATS Exchange in USA. It is located in PENNSYLVANIA U.S.A and employs 25 people. Onconova Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.
Onconova Therapeutics Leadership Team
Stock Performance Indicators